GLP1R and diabetes mellitus: Our analyses support the recommendation that anti-hyperglycemic drugs should be chosen with preference in diabetes patients with established CVD or at high cardiovascular risk, with GLP1R agonists and also sodium–glucose cotransporter 2 inhibitors [35] as priority, after considering drug-specific and patient factors.